报价延迟最少15分钟:2026/04/15 09:41 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.8136 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.35/-0.94
|
|
企业价值
776.33M
|
| 资产负债 |
|
每股账面净值
0.67
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
4.63M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations,acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need. |
